Nervgen Pharma (NGEN) Annual Balance Sheets

Annual · GAAP · USD millions
Access NGEN quarterly Balance Sheets →
This balance sheet overview for Nervgen Pharma spans from to Dec 31 2025, showing how the company's assets, liabilities, and equity have evolved across reporting periods.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2025)
Assets
Cash And Cash Equivalents16.10
Cash & Short-term Investments16.00
Trade & Other Current Receivables (IFRS combined total)0.06
Other Current Assets0.56
Total Current Assets16.63
Intangible Assets0.30
Tax Assets, Noncurrent19.96
Other Assets, Noncurrent0.31
Trade And Other Current Receivables0.06
Prepayments Deposits And Other Current Assets0.49
Current Net Investment In Lease0.01
Intangible Assets Other Than Goodwill0.31
Noncurrent Assets0.31
Total Assets16.93
Liabilities
Accounts Payable3.40
Other Liabilities, Current15.12
Total Current Liabilities14.39
Total Long-term Debt0.00
Total Liabilities14.39
Stockholders' Equity
Other Equity2.66
Common Stockholder's Equity2.66
Total Stockholder's Equity2.54
Liabilities & Stockholder's Equity16.93
4 historic quarters locked

Sign in to unlock the full Nervgen Pharma balance sheet history.

About Nervgen Pharma Corp Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 40-F filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001104659-26-037357

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License